Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 151

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 151
---
 results of
operations and continued growth depend, in part, on its ability in a timely manner to develop or acquire rights to, and successfully introduce
into the marketplace, enhancements of existing products and services or new products and services that incorporate technological advances,
meet customer requirements, and respond to products developed by DiamiR’s competition. DiamiR cannot provide any assurance that
it will be successful in developing or acquiring such rights to products and services on a timely basis, or that such products and services
will adequately address the changing needs of the marketplace, either of which could adversely affect DiamiR’s results of operations.

In addition, DiamiR must regularly
allocate considerable resources to research and development of new products, services and technologies. The research and development process
generally takes a significant amount of time from design stage to product launch. This process is conducted in various stages. During
each stage, there is a risk that DiamiR will not achieve its goals on a timely basis, or at all, and DiamiR may have to abandon a product
in which DiamiR has invested substantial resources.

<div align='center'>71</div>

If DiamiR’s laboratory becomes inoperable for any reason, DiamiR will be unable to perform its testing and its business will be harmed.

The laboratory and equipment
DiamiR uses to perform its tests and services would be costly to replace and could require substantial lead time to replace and qualify
for use if they became inoperable. DiamiR ’s facilities may be harmed or rendered inoperable by natural or man-made disasters, including
earthquakes, flooding, power outages, and health epidemics or pandemics, including the outbreak of Coronavirus (COVID-19), which may render
it difficult or impossible for DiamiR to perform its testing or services for some period of time, or to receive and store samples. The
inability to perform its tests or services for even a short period of time, including due to disruption in staffing, supplies, distribution,
or transport or temporary closures related to an outbreak of disease such as COVID-19, may result in the loss of customers or harm its
reputation, and DiamiR may be unable to regain those customers in the future.

If DiamiR’s landlord does not renew its lease, its clinical and testing operations will be halted until DiamiR locates and sets up a new laboratory.

DiamiR currently has a one
year lease ending in December 2025